In this article by Rogers and colleagues (BMJ 2017;358:j1951, doi:10.1136/bmj.j1951), the third bullet point in the “What’s new in this guidance” box stated: “Guidance for advanced Parkinson's disease, recommending deep brain stimulation (but not levodopa-carbidopa intestinal gel) for people whose symptoms are not adequately controlled by best medical therapy.” In fact, NICE did not specifically state not to use levodopa-carbidopa intestinal gel in the recommendation, so the text should have read: “Guidance for advanced Parkinson's disease, recommending deep brain stimulation for people whose symptoms are not adequately controlled by best medical therapy.”